Novo Nordisk Bets on AI and New Products to Reverse Steep Share Slide

Novo Nordisk shares rebound on UK Wegovy pen approval. The firm combats a weak outlook with an OpenAI AI partnership and a DKK 15B share buyback program.

Novo Nordisk shares found some relief this week, climbing over 9% on a seven-day view to trade at €34.90. The uptick follows a critical regulatory approval in the UK for a new, more flexible 7.2mg single-dose Wegovy pen for adults with obesity, which management hopes will improve long-term patient adherence. The news sparked significant trading activity, with nearly 20 million shares changing hands on the announcement day.

This positive development arrives as the Danish pharmaceutical giant navigates a punishing market environment. Since the start of the year, the stock has shed nearly 22% of its value, trading more than 50% below its 52-week high of over €70 euros. The three months leading to April were particularly brutal, witnessing a 36% decline driven primarily by a weak financial outlook.

That outlook remains a major headwind. For the full year 2026, Novo Nordisk forecasts a currency-adjusted sales decline of between 5% and 13%, with operating profit expected to follow a similar downward trajectory. Analysts at BMO Capital have echoed these concerns, cutting their price target on the stock. They warn that a high volume of lower-priced Wegovy doses could pressure revenue, potentially causing the company to miss first-quarter 2026 consensus estimates by as much as 12%.

In response to these challenges, Novo Nordisk is executing a two-pronged strategy focused on technological transformation and financial engineering. The company has embarked on a sweeping partnership with OpenAI to embed artificial intelligence across its entire operation—from drug discovery labs to the global supply chain. Pilot projects in research, manufacturing, and sales are launching immediately, with full integration targeted by the end of 2026.

CEO Mike Doustdar framed the AI push as essential for accelerating new therapies for millions of diabetes and obesity patients. OpenAI's Sam Altman stated the collaboration aims to speed up scientific discovery and redefine patient care, with strict data governance ensuring ethical use. This deal builds on an existing research partnership with chipmaker Nvidia, placing Novo Nordisk squarely in an industry-wide technological arms race. Rival Eli Lilly, for instance, signed its own AI partnership with Insilico Medicine in March.

Simultaneously, the company is deploying its substantial financial resources to support its share price. A DKK 15 billion share buyback program is underway. Between February and mid-April, Novo Nordisk repurchased approximately 11 million B shares, including 1.04 million acquired between April 7 and 10 at an average price of DKK 257.56. The company now holds 28.4 million of its own shares, equivalent to 0.6% of its total share capital.

This aggressive capital return is backed by a still-robust financial foundation; the firm posted a net profit of DKK 102 billion in 2025. Management is channeling profits into scaling production capacity for its blockbuster weight-loss drugs, a necessary move amid significant price pressure in the key US market and high investment costs.

The road ahead holds key milestones. The expected inclusion of obesity medications in US Medicare Part D coverage around mid-year is one. The other is the completion of its company-wide AI overhaul by late 2026. For now, Novo Nordisk is leveraging every tool—from regulatory wins and share repurchases to a bold AI bet—in an attempt to stabilize its course after a precipitous fall.